US$ 27.95
glp-1 clinical studies Changes in weight with RAs in head-to-head studies. *p < Issue 42: GLP-1 RA Drug
Description
Both Zepbound (tirzepatide) and Wegovy (semaglutide GLP-1) typically begin to show noticeable effects on appetite and weight within the first month of treatment
however, commonly used antidiabetic medications are also associated with adverse GI effects

All GLP-1 RA labels mention to monitor for pancreatitis signs

Tirzepatide has been granted FDA approval for treatment of type 2 diabetes based primarily on a series of trials known as SURPASS

Circulation, 145(8), 575585
